national organization rare disorders nord distributed following message members kda participated initial solicitation support current proposed guidelines falls little short asking patient input kennedy disease als ms example i believe would like say process especially disease progresses nord message plus link letter update benefit risk assessments benefit risk assessments basis fda regulatory decisions pre market post market review process drugs biologics patient voice process critical letter fda september expressed hope patients patient organizations would able contribute toward agency decision making assessing benefit risk equation new products well amount risk patients various stages condition willing take quality life challenges face ways receive information proper use therapies often see receive information physicians information fda medical reviewers relevant fda staff may benefit knowing directly patients fda published draft proposed approach benefit risk assessment drug regulatory decision making february unfortunately draft currently written falls short expectations include patient voice process please review comments fda due may voice support comments critical sign comments please contact diane dorman ddorman rarediseases org later monday april additional questions please hesitate contact view letter paragraph linked letter needs reinforcing believe benefit risk framework would substantially improved revised include meaningful timely involvement patients fda also establish mechanisms communicate patients receive information patients enhance factual basis individual benefit risk assessments real time mechanism would serve fda goal avoiding incorrect assumptions patient risk tolerance well providing contextual information key benefit risk framework also believe fda exercise leadership include patients include regulated industry resources develop kinds contextual data fda seeks new drugs particularly address unmet medical needs continuously offered review fda needs enhanced timetable assuring patient input interested i recommend contact senators representatives expressing support patient involvement benefit risk assessment process